Patrick Blaney

Has grant

Senior Bioinformatics Programmer

NYU Langone Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Role of disadvantage, mutographs and T cell immunity on MGUS in African Americans

Open Date: 2025-01-01

Close Date: 2030-01-01

Grant: Close

Using mutographs to define the molecular landscape and cell of origin of Waldenstrom’s Macroglobulinemia

Open Date: 2023-01-01

Close Date: 2025-01-01

Grant: Close

Polyethnic-1000

Open Date: 2021-01-01

Close Date:

Grant: Close

Mutographs differentiating the racial and temporal incidence of Multiple Myeloma

Open Date: 2021-01-01

Close Date: 2026-01-01

Articles (61)

The H3K36me2 methyltransferase NSD2 is deleted in Wolf-Hirschhorn syndrome and aberrantly expressed in 10-15% of multiple myeloma (MM) due to a t(4;14) translocation. Although NSD2 is thought to be a primary driver in MM, the exact molecular mechanisms by which it regulates transcription remain unclear. We applied the dTAG system to acutely degrade NSD2 and used this, in combination with time-resolved SLAM-seq, to identify 307 transcriptional targets of NSD2. Reconstitution with either wild-type NSD2 or a catalytically inactive mutant (NSD2Y1179A) showed that NSD2's transcriptional effects are almost exclusively dependent on its SET domain activity. Mechanistically, H3K36me2 deposition by NSD2 antagonizes H3K27me3 levels, and treatment with two distinct PRC2 inhibitors demonstrated that approximately half of NSD2 target genes are regulated in an H3K27me3-dependent manner. CUT&Tag analysis showed that upon NSD2 depletion there was an increase in H3K27me3 that occurred at genome-wide intergenic regions, rather than at the promoters or gene bodies of NSD2 target genes. These data suggest that NSD2, via H3K36me2, antagonizes H3K27me3 deposition likely at distal regulatory elements including enhancers, creating a chromatin landscape favorable for target gene transcription. Importantly, NSD2 target genes were enriched for key oncogenic pathways, and 24 transcription factors implicated in neurodevelopment and acute leukemia, consistent with its role in Wolf-Hirschhorn syndrome and MM. Eight of these transcription factors are known oncogenic drivers in acute leukemia or MM, highlighting a novel molecular mechanism for NSD2's role in t(4;14) MM.

Year:

2026

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.

Year:

2026

Year:

2026

Year:

2026

Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that a preferred alternative to self-described race is using ancestry-informative markers (AIMs) that can be classified into ancestral components and used to estimate their similarity to those of known populations to identify continental groups. However, real-world genomic data can present challenges, including limited availability of germline DNA, a small number of AIMs for each sample, and the use of different variant calling software, limiting the application of existing solutions. Results Here, we describe a novel supervised machine-learning tool AncestryGeni, which infers genetic ancestry for samples with even a hundred markers and is applicable to any genomic data, including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) data. Applying AncestryGeni to a real-world genomic dataset obtained from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, we show that it is more accurate than the commonly used FastNGSadmix when using nonstandard genomic material. We also demonstrate that when using AncestryGeni, the tumor-derived sequence obtained from WES and RNA-Seq can be a robust data source to accurately estimate an individual’s genetic similarity to a continental group. Availability and implementation AncestryGeni pipeline is available at https://github.com/eelhaik/AncestryGeni/tree/main.

Year:

2025

Year:

2025

We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.

Year:

2025

Background The bone marrow (BM) niche contains non-hematopoietic elements including mesenchymal stromal cells (MSC) and bone marrow endothelial cells (BMEC) which provide mechanical support, and control hematopoietic cell growth and differentiation. Although it is known that multiple myeloma (MM) cells interact closely with the BM microenvironment, little is known about the impact of MM on non-hematopoietic niche-forming cells. Methods To address the role of the niche in MM pathogenesis, we utilized the 5TGM1 murine model. During the asymptomatic precursor stage of the model, we isolated the rare non-hematopoietic cells and performed single cell RNA sequencing. Using in-silico methods we characterized the individual cellular components of the niche, their relative abundance and differentiation state before and after exposure to MM cells as well as their intercellular interactions. Results MM engraftment increased the abundance of MSC-lineage cells, BMECs and enhanced endothelial to mesenchymal transition. An inflammatory and oxidative stress signal was identified together with polarization of MSC differentiation away from osteocyte formation towards adipocytes which provide growth factors that are known to support MM expansion. BMEC differentiation was polarized towards sinusoidal endothelial cells with a pro-angiogenic/pro-inflammatory phenotype. Conclusions MM cells impact the BM niche by generating a pro-inflammatory microenvironment with MSC differentiation being changed to generate cell subsets that favor MM growth and survival. In order to induce remission and improve long-term outcome for MM patients these inflammatory and oxidative stress signals need to be reduced and normal niche differentiation trajectories restored.

Year:

2025

Chromatin state of varying deleted regions. There is a greater variability in terms of chromatin composition of the lost regions in comparision to the region of gain. The D1 region had identical an A-compartment percentage (56%) across all samples and reflected loss of significant subtelomeric region, including TNFRSF4. The D2 region was consistent across all samples (range 96-100% A-compartment) with the exception of KMS11 (47%), however this switch to a B-compartment occurred in a gene-sparse region. The D3 region encompasses the tumour suppressor genes CDKN2C and FAF1 and had similar active chromatin profiles (range 44-77%) except in RPMI8226 (0%). The D4 and D5 regions lie completely (100%) and near completely (>87%) in inactive compartments. Interestingly, the small A-compartments in D5 across U266 and RPMI8226 correspond to the tumour suppressor FUBP1. The D6 region showed conserved A-compartment across the samples specifically at the RPL5 and MTF2 loci while EVI5 and GFI1 showed switching from B-A across the differentiation stages. The D7 region, focused on TENT5C lies within an A-compartment across all samples except for KMS11, NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.

Year:

2025

Chromatin state of different SV regions. The CT1 region at 1p36.11-1p34.3 is comprised of greater than 74% A-compartment (range 74-100%); CT2 at 1p33-1p32.3 comprises both inactive (range 35-59%) and active chromatin (range 41-65%) and, CT3 at 1p13.3-1p12, overlaps with TI1, had greater variability with 86% A-compartment in U266 while only 1% in KMS11. TI1 region predominantly laid in B-compartment (range 63-73%) and TI2 lay in an almost entirely active compartment (range 91-100%). NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (27)

Marc Braunstein

-

UNITED STATES
View details

Behnam Nabet

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Esteban Braggio

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Xiaoyi Chen

Assistant professor

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

David Kaminetzky, M.D.

Assistant Professor (Clinical) of Medicine

NYU School of Medicine

UNITED STATES
View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Jill Corre

-

FRANCE
View details

Arnaldo Arbini

Associate Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Aristotelis Tsirigos

Associate Professor (Research) of Pathology

NYU School of Medicine

UNITED STATES
View details

Giancarlo Castellano

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Michael Bauer

Associate Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

David G. Coffey

Assistant Professor

University of Miami School of Medicine

UNITED STATES
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Benedetto Bruno

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY
View details

Lukas John

Deutsches Krebsforschungszentrum

GERMANY
View details

Irene Ghobrial

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Florence Nguyen-Khac

Sorbonne Université

FRANCE
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Gaurav Varma

Assistant Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Dickran Kazandjian

University of Miami

UNITED STATES
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Eran Elhaik

Associate Professor

Lund University

SWEDEN
View details

Juan-José Garcés

Research Scholar

Sloan Kettering Institute

UNITED STATES
View details